Used in Lieu of PTO/SB/08A/B
(Based on PTO 10-07 version)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known	
Application Number	10/521,334
Filing Date	October 27, 2005
First Named Inventor	Mikhail I. Papisov
Art Unit	1626
Examiner Name	Chu, Yong Liang
Attorney Docket Number	0492479-0041 (MGH 2170 US)

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1*	US-5,075,222	12-24-1991	Hannum et al.	
	A2*	US-5,582,172	12-10-1998	Papisov et al.	
	A3*	US-5,624,803	04-29-1997	Noonberg et al.	
	A4*	US-5,811,510	09-22-1998	Papisov	
	A5*	US-5,817,343	10-06-1998	Burke	
	A6*	US-5,824,784	10-20-1998	Kinstler et al.	
	A7*	US-5,863,990	01-26-1999	Papisov	
	A8*	US-5,958,398	09-28-1999	Papisov	
	A9*	US-6,048,837	04-11-2000	Friedman et al.	
	A10*	US-6,057,431	05-02-2000	Ishihara et al.	
	A11*	US-6,294,170	09-25-2001	Boone et al	
	A12*	US-20020082362	06-27-2002	Brocchini et al.	
	A13*	US-20040105840	06-03-2004	Kinstler et al.	
	A14*	US-6,822,086	11-23-2004	Papisov	
	A15*	US-20050169988	08-04-2005	Elmaleh et al.	
	A16*	US-20060019911	01-26-2006	Papisov	
	A17*	US-20080069230	03-30-2008	Papisov	
	A18*	US-7,180,924	01-09-2007	Kinstler et al.	
	A19*	US-20070190018	08-16-2007	PAPISOV	
	A20*	US-7,270,808	09-18-2007	Cheng et al.	
	A21*	US-20080019940	01-24-2008	Papisov	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	B1	EP-0280474-A2	08-31-1988	Johnson Matthey Inc		
	B2	EP-0325270-A2	07-26-1989	Green Cross Corp		
	B3	WO-9805309-A2	02-22-1998	Univ Rockefeller et al		
	B4	WO-9640912-A1	12-19-1996	Amgen Inc		
	B5	WO-9930561-A1	06-24-1999	Nexstar Pharmaceuticals Inc		
	B6	WO-0107486-A1	02-01-2001	Polygene Ltd et al		
	B7	WO-0110468-A2	02-15-2001	Gen Hospital Corp et al		
	B8	WO-03059988-A2	07-24-2003	Gen Hospital Corp et al		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]

4597783v1		Date Considered	

Used in Lieu of PTO/SB/08A/B
(Based on PTO 10-07 version)

Substitute for form 1449/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)* Sheet 2 of 3	*Complete if Known*	
	Application Number	**10/521,334**
	Filing Date	October 27, 2005
	First Named Inventor	Mikhail I. Papisov
	Art Unit	1626
	Examiner Name	Chu, Yong Liang
	Attorney Docket Number	0492479-0041 (MGH 2170 US)

	C1	Conover, C et al. Physiological Effect of Polyethylene Glycol Conjugation on Stroma-Free Bovine Hemoglobin in the Conscious Dog After Partial Exchange Transfusion, Artificial Organs, Vol 21, No 5, 1997, pp 369-376	
	C2	Endo et al Nature of Linkage and Mode of Action of Methotrexate Conjugated with Antitumor Antibodies: Implications for Future Preparation of Conjugates. Cancer Research. (1966), 46, p. 3330-3335	
	C3	Feng et al Bioorg Med. Chem. Lett (2002) 12, pp. 3301-3303	
	C4	Gao Q et al Drug-induced DNA repair X-ray structure of a DNA-ditercalinium complex Proc Natl. Acad Sci. USA Vol 66, pp 2422-2426, March 1991 Biochemistry	
	C5	Jordan, V. C Nature Reviews: Drug Discovery, 2, 2003, p. 205-213	
	C6	Maeda, H et al Conjugates of anticancer agents and polymers advantages of macromolecular therapeutics in vivo. Bioconj. Chem. 1992, 3 351-362	
	C7	Matysiak S Acetal Oligonucleotide Conjugates In Antisense Strategy Nucleosides & Nucleotides, 16(5&6), pp 655-661 (1997)	
	C6	Papisov M.I. et al. Semisynthetic Hydrophilic Polyals Biomacromolecules 2005, vol. 6, pp 2659-2670	
	C9	Papisov, M et al. Fully biodegradable hydrophilic polyals (polyacetals and polyketals). 29th Int. Symp. on Controlled Release of Bioactive Materials, 2002, Seoul, Korea Controlled Release Society, Deerfield, IL, 2002; paper # 465	
	C10	Papisov, M. (2001) Acyclic polyacetals from polysaccharides. (Biopolymers from polysaccharides and agroproteins), ACS Symposium Series 766, pp 301-314	
	C11	Papisov, M. et al (1996) A long-circulating polymer with hydrolizable main chain 23-rd International Symposium on Controlled Release of Bioactive Materials, Kyoto, Japan, 1996; Controlled Release Society, Deerfield, IL,; 107-106	
	C12	Papisov, M. et al. Fully biodegradable hydrophilic polyacetals for macromolecular radiopharmaceuticals. 49-th Annual Meeting of The Society of Nuclear Medicine, Los Angeles, CA, 2002. J. Nuc. Med 2002, 43 5 (Supplement) p. 377P (abstract)	
	C13	Papisov, M. et al. Hydrophilic Polyals: Biomimetic Biodegradable Stealth Materials for Pharmacology and Bioengineering Proceedings of 226th Natl Meeting of American Chemical Society, New York, NY, 2003	
	C14	Papisov, MI et al. (1996) Model cooperative (multivalent) vectors for drug targeting 25th Int. Symp. on Controlled Release of Bioactive Materials, 1996, Las Vegas, Nevada, USA; Controlled Release Society, Deerfield, IL,170-171	
	C15	Papisov, MI. Modeling in vivo transfer of long-circulating polymers (two classes of long circulating polymers and factors affecting their transfer in vivo) Adv Drug Delivery Rev , Special issue on long circulating drugs and drug carriers, 1995, 16 127-139	
	C16	Papisov, MI. Theoretical considerations of RES-avoiding liposomes: molecular mechanics and chemistry of liposome interactions. Adv Drug Delivery Rev 1998, 32:119-138	
	C17	Tomlinson et al Polyacetal-doxorubicin conjugates designed for pH dependent degradation Bioconjugate Chem., 2003, 14(6), 1096-1106	
	C18	Yurkovetskiy, A et al Biodegradable polyal carriers for protein modification 29th Int Symp on Controlled Release of Bioactive Materials, 2002, Seoul, Korea. Controlled Release Society, Deerfield, IL, 2002; paper # 357	
	C19	Yurkovetskiy, A et al Biodegradable polyals for protein modification Controlled Release Society's Winter Symposium, Salt Lake City, Utah, 2003	
	C20	Yurkovetsky, A et al., Fully Degradable Hydrophilic Polyals for Protein Modification Biomacromolecules 2005, 6, 2648-2658	
	C21	Zalipsky et al Eur Polym J. (1983), Vol. 19, No. 12, p 1177-1183	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Used in Lieu of PTO/SB/08A/B
(Based on PTO 10-07 version)

Substitute for form 1449/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*				***Complete if Known***	
				Application Number	**10/521,334**
				Filing Date	October 27, 2005
				First Named Inventor	Mikhail I. Papisov
				Art Unit	1626
				Examiner Name	Chu, Yong Liang
Sheet	3	of	**3**	**Attorney Docket Number**	0492479-0041 (MGH 2170 US)

considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.